Q4 Revenue Accelerates 62% on Strong US Launch
InspireMD (NASDAQ: NSPR) announced on March 18, 2026, that its fourth-quarter 2025 revenue reached $3.1 million, a 62% increase from the $1.9 million recorded in the same period of 2024. The performance was driven by the early commercial success of its CGuard Prime carotid stent system in the United States. U.S. revenue, in just its second quarter of launch, hit $0.9 million, representing 74% sequential growth and demonstrating rapid market adoption. International revenue also grew, rising 17% to $2.3 million as the company deepened its penetration in existing markets.
Margins Expand as Net Loss Narrows to $0.14 Per Share
The strategic focus on the higher-margin U.S. market directly boosted the company's financial health. Gross profit for the quarter more than doubled to $1.2 million, expanding the gross margin to 37.5% from 24.1% in Q4 2024. This improved efficiency contributed to a smaller net loss of $11.8 million, or $0.14 per share. The figure marks a notable improvement from the $0.19 per share loss a year ago and came in well ahead of the Zacks Consensus Estimate of a $0.22 loss per share.
Company Guides for Up to 65% Growth in 2026
Buoyed by its recent performance, InspireMD issued a robust initial revenue forecast for the full year 2026, projecting sales between $13 million and $15 million. This guidance implies an anticipated growth rate of 45% to 65% compared to the $9.0 million revenue generated in full-year 2025. The positive outlook underscores management's confidence in the continued adoption of its CGuard stent platform as it works to establish a leadership position in stroke prevention. CEO Marvin Slosman noted the "robust early momentum" and expects further catalysts to accelerate growth in 2026.
Edgen Stock·Mar 18 2026, 13:47
